Amiloride ( DrugBank: Amiloride )


4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎5
67多発性嚢胞腎2
225先天性腎性尿崩症3
299嚢胞性線維症3

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01910259
(ClinicalTrials.gov)
December 18, 201419/7/2013MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation TrialA Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.Secondary Progressive Multiple SclerosisDrug: Amiloride;Drug: Riluzole;Drug: Fluoxetine;Drug: PlaceboUniversity College, LondonMedical Research Council;National Institute for Health Research, United Kingdom;MS Society;University of Edinburgh;Queen Mary University of London;Keele University;University of Sheffield;University of Leeds;University of WarwickCompleted25 Years65 YearsAll445Phase 2United Kingdom
2EUCTR2012-005394-31-GB
(EUCTR)
01/04/201405/09/2014MS-SMART: A Trial of Efficacy (usefulness) of 3 Neuroprotective Drugs in SPMSMS-SMART: A Multi-Arm Phase IIb Randomised, Double Blind Placebo-Controlled Clinical Trial Comparing The Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis - MS-SMART: Multiple Sclerosis Secondary Progressive Multi-Arm Randomisation Trial Mutliple Sclerosis (Secondary Progressive);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Rilutek
Product Name: Rilutek
INN or Proposed INN: Riluzole
Trade Name: Amiloride
Product Name: Amiloride
INN or Proposed INN: Amiloride
Trade Name: Fluoxetine
Product Name: Fluoxetine
INN or Proposed INN: Fluoxetine hydrochloride
UCLNULLNot Recruiting Female: yes
Male: yes
440 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom
3EUCTR2012-005113-39-AT
(EUCTR)
08/04/201318/02/2013Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve.A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis - Amiloride Hydrochlorothiazide in acute autoimmune optic neuritis Optic neuritis is among the most common first symptoms of multiple sclerosis leading to significant atrophy of the optic nerve within a short period of time, thus reflecting neurodegneration.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Trade Name: Amilostad HCT
Product Name: Amilostad HCT tablets
INN or Proposed INN: AMILORIDE HYDROCHLORIDE, 2 H2O
Other descriptive name: Amiloride Hydrochloride
INN or Proposed INN: hydrochlorothiazide
Other descriptive name: HYDROCHLOROTHIAZIDE
Universitätsklinik für Neurologie, Medizinische Universität WienNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Austria
4NCT01802489
(ClinicalTrials.gov)
February 201327/2/2013Amiloride Clinical Trial In Optic NeuritisA Double Blind Randomised Control Trial on Neuroprotection of Amiloride in Optic NeuritisOptic Neuritis;Multiple SclerosisDrug: Amiloride;Drug: PlaceboUniversity of OxfordMultiple Sclerosis Society of Great Britain and Northern IrelandCompleted18 Years55 YearsAll46Phase 2United Kingdom
5EUCTR2007-004051-11-GB
(EUCTR)
18/12/200815/07/2008Amiloride Treatment in Multiple Sclerosis - Amiloride in MSAmiloride Treatment in Multiple Sclerosis - Amiloride in MS Multiple SclerosisTrade Name: Amiloride
Product Name: Amiloride Hydrochloride
Oxford Racliffe NHS TrustNULLNot RecruitingFemale: yes
Male: yes
23United Kingdom

67. 多発性嚢胞腎


臨床試験数 : 221 薬物数 : 212 - (DrugBank : 55) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 151
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05228574
(ClinicalTrials.gov)
March 11, 202212/1/2022Treatment of Vascular Stiffness in ADPKDTreatment of Vascular Stiffness in Patients With Autosomal Dominant Polycystic Kidney DiseaseAutosomal Dominant Polycystic KidneyDietary Supplement: Sodium chloride (NaCl);Dietary Supplement: Placebo;Drug: Amiloride Hcl 5mg TabErasmus Medical CenterNULLRecruiting18 YearsN/AAll54Phase 4Netherlands
2EUCTR2020-000433-40-NL
(EUCTR)
30/12/202103/08/2021Treatment of stiffness in blood vessels in patients with familial cystic kidney diseaseTreatment of vascular stiffness in patients with autosomal dominant polycystic kidney disease - TRAMPOLINE Autosomal dominant polycystic kidney disease;Therapeutic area: Not possible to specifyTrade Name: Amiloride
Product Name: Amiloride
INN or Proposed INN: AMILORIDE
Trade Name: Sodium Chloride
INN or Proposed INN: Sodium chloride
Other descriptive name: Sodium Chloride
Erasmus University Medical Centre RotterdamNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
54Phase 4Netherlands

225. 先天性腎性尿崩症


臨床試験数 : 15 薬物数 : 48 - (DrugBank : 18) / 標的遺伝子数 : 31 - 標的パスウェイ数 : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05044611
(ClinicalTrials.gov)
January 11, 202327/8/2021AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With LithiumAMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium: a Randomized Controlled TrialBipolar DisorderDrug: Anhydrous Amiloride Hydrochloride;Drug: PlaceboAssistance Publique - Hôpitaux de ParisNULLRecruiting18 Years70 YearsAll148Phase 4France
2NCT00478335
(ClinicalTrials.gov)
May 200723/5/2007Pharmacologic Treatment of Congenital Nephrogenic Diabetes InsipidusPharmacologic Treatment of Congenital Nephrogenic Diabetes InsipidusNephrogenic Diabetes InsipidusDrug: sildenafil;Drug: calcitonin;Drug: hydrochlorothiazide/amiloride;Drug: indomethacin;Drug: Placebo for sildenafil;Drug: placebo for calcitoninUniversity of Colorado, DenverUniversity of AarhusCompleted5 Years25 YearsMale4N/AUnited States;Denmark
3EUCTR2006-001202-84-NL
(EUCTR)
01/02/200731/01/2007Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDI Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDI Lithium-induced Nephrogenic Diabetes Insipidus
MedDRA version: 9.1;Level: LLT;Classification code 10012600;Term: Diabetes insipidus nephrogenic
Trade Name: Midamor
Product Name: Amiloride
Trade Name: Hydrochloorthiazide
Product Name: hydrochloorthiazide
Radboud University Nijmegen Medical CentreNULLNot RecruitingFemale: yes
Male: yes
50Phase 4Netherlands

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00547053
(ClinicalTrials.gov)
December 200617/10/2007Amiloride Solution and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic FibrosisA Six Month Open Label Study of Amiloride Solution for Inhalation and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic FibrosisCystic FibrosisDrug: Amiloride Solution for InhalationChildren's Hospital BostonCystic Fibrosis Foundation TherapeuticsCompleted6 YearsN/ABoth25Phase 1United States
2NCT00274391
(ClinicalTrials.gov)
July 20019/1/2006Efficacy of Amiloride and Hypertonic Saline in Cystic FibrosisEfficacy of Amiloride and Hypertonic Saline in Cystic FibrosisCystic FibrosisDrug: 7% NaCl;Drug: Amiloride HClUniversity of North CarolinaCystic Fibrosis Foundation TherapeuticsCompleted14 YearsN/ABoth24Phase 2United States
3NCT00004705
(ClinicalTrials.gov)
September 199624/2/2000Study of Uridine Triphosphate (UTP) as an Aerosol Spray for Cystic FibrosisCystic FibrosisDrug: amiloride;Drug: uridineFDA Office of Orphan Products DevelopmentUniversity of North CarolinaCompleted4 YearsN/ABothN/ANULL